We are experts in innovation. We define what’s next and make it reality. Each Miraki portfolio company enjoys the full force of our knowledge, expertise and resources. Our history of building and investing in companies to solve global health issues began over a decade ago.
To date, we have proven success in orthopedics, surgical robotics, aesthetics, oncology, tissue regeneration, infectious disease, imaging and diagnostics, cardiology, trauma and all forms of surgery. Our investments deliver superior technology to solve pressing problems aimed to reduce suffering, change and save lives and to make medical technology more efficacious, patient-specific and accessible.
Founded by Chris Velis in 2007 and funded in our beta fund, Auris Health’s upcoming acquisition by Johnson & Johnson was announced on Feb. 13, 2019. Now valued at $5.75 billion (inclusive of milestone payments), Auris Health is one of medtech’s most valuable assets and its only unicorn. This transaction with Johnson & Johnson is touted as the single largest venture-funded medtech acquisition in history. Through an integrated platform that encompasses AI, VR, guidance, visualization and miniaturization systems, Auris’ surgical robots give providers and patients access to procedures that could not otherwise be performed in a minimally-invasive manner. In 2018, the company gained regulatory clearance for the diagnosis of lung cancer and was recognized by CNBC as one of the 50 most disruptive companies in the world.
Developed to offer the orthopedic and spine surgery markets a reliable technology to accelerate bone growth and healing, Cerapedics’ products are designed to be a safer and more predictable bone formation factor than those commercially available. Cerapedics’ iFACTOR™ Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process and is the only orthobiologic with regulatory clearance for cervical spinal fusion procedures.
Audax’s Arxis™ is a next-generation tissue regenerative medical device. Upon regulatory clearance, the technology will not only be utilized to regenerate bone, cartilage and soft tissue, deliver biologic agents and pharmaceuticals, but also has applications in the regeneration of skin for use in aesthetic procedures. Arxis aims to replace standard bone fillers that are limited in both mechanical and healing capabilities. This innovative device is a self-assembling, bioresorbable nanocomposite made of the same compounds as human DNA. It is designed to be used in minimally-invasive orthopedic reconstructive surgery and aesthetic plastic surgery procedures.
Arctic Fox Biomedical
Arctic Fox Biomedical aims to address the growing demand in aesthetic medicine. The portfolio company’s products will enhance physicians’ capabilities to address the demands of the growing number of clients seeking hassle-free personal enhancement procedures.
Investment Stage: Series B
BOA Biomedical (BOA) has a platform technology for rapid diagnosis and treatment of infectious diseases. Developed at the Wyss Institute for Biologically Inspired Engineering, BOA licensed the initial technology for this medical device from Harvard University in 2018.
Investment Stage: Series A